Genmab A/S (NASDAQ:GMAB) Sets New 52-Week Low - Should You Sell?

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s share price hit a new 52-week low on Tuesday . The stock traded as low as $17.77 and last traded at $17.98, with a volume of 1942101 shares. The stock had previously closed at $18.19.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on GMAB shares. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research note on Wednesday. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Truist Financial lowered their price target on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Finally, Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Trading Up 4.4 %

The company has a market cap of $12.45 billion, a price-to-earnings ratio of 10.81, a P/E/G ratio of 2.65 and a beta of 1.07. The stock's 50-day moving average is $20.48 and its 200-day moving average is $21.31.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of the company. Legacy Wealth Asset Management LLC grew its position in Genmab A/S by 36.7% in the 1st quarter. Legacy Wealth Asset Management LLC now owns 49,367 shares of the company's stock valued at $967,000 after purchasing an additional 13,246 shares during the period. GAMMA Investing LLC lifted its stake in shares of Genmab A/S by 1,465.3% in the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock valued at $656,000 after buying an additional 31,343 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of Genmab A/S by 1,108.3% in the first quarter. Versant Capital Management Inc now owns 8,724 shares of the company's stock valued at $171,000 after buying an additional 8,002 shares in the last quarter. Marotta Asset Management grew its holdings in shares of Genmab A/S by 5.8% during the first quarter. Marotta Asset Management now owns 13,532 shares of the company's stock valued at $265,000 after buying an additional 739 shares during the last quarter. Finally, Employees Retirement System of Texas bought a new stake in shares of Genmab A/S during the fourth quarter worth about $1,648,000. Institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.